Index -
P/E 34.80
EPS (ttm) 0.65
Insider Own 2.76%
Shs Outstand 302.79M
Perf Week -1.27%
Market Cap 6.83B
Forward P/E 14.51
EPS next Y 1.55
Insider Trans -0.18%
Shs Float 294.81M
Perf Month -5.02%
Income 207.76M
PEG 1.83
EPS next Q 0.23
Inst Own 87.10%
Short Float 2.32%
Perf Quarter 0.18%
Sales 1.83B
P/S 3.73
EPS this Y 91.37%
Inst Trans -1.96%
Short Ratio 3.00
Perf Half Y 5.48%
Book/sh 7.48
P/B 3.01
EPS next Y 24.78%
ROA 6.85%
Short Interest 6.83M
Perf Year 17.54%
Cash/sh 3.28
P/C 6.86
EPS next 5Y 19.00%
ROE 8.74%
52W Range 18.08 - 24.34
Perf YTD -6.13%
Dividend Est. -
P/FCF 23.31
EPS past 5Y -21.77%
ROI 8.47%
52W High -7.48%
Beta 0.58
Dividend TTM -
Quick Ratio 3.30
Sales past 5Y 17.31%
Gross Margin 96.04%
52W Low 24.56%
ATR (14) 0.53
Dividend Ex-Date -
Current Ratio 3.34
EPS Y/Y TTM 15.07%
Oper. Margin 9.34%
RSI (14) 42.80
Volatility 2.39% 2.20%
Employees 1310
Debt/Eq 0.10
Sales Y/Y TTM 13.60%
Profit Margin 11.35%
Recom 1.73
Target Price 26.73
Option/Short Yes / Yes
LT Debt/Eq 0.08
EPS Q/Q 392.82%
Payout 0.00%
Rel Volume 1.02
Prev Close 22.49
Sales Surprise -0.14%
EPS Surprise 17.54%
Sales Q/Q 13.15%
Earnings Apr 30 AMC
Avg Volume 2.27M
Price 22.52
SMA20 -3.56%
SMA50 0.66%
SMA200 3.57%
Trades
Volume 2,329,664
Change 0.13%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-11-24 Downgrade
Barclays
Overweight → Equal Weight
$25
Dec-19-23 Initiated
BTIG Research
Buy
$27
Dec-15-23 Initiated
Citigroup
Buy
$31
Sep-26-23 Initiated
H.C. Wainwright
Buy
$28
Aug-22-23 Reiterated
Oppenheimer
Outperform
$25 → $29
Aug-08-23 Initiated
SVB Securities
Market Perform
$18
Jul-11-23 Resumed
Morgan Stanley
Equal-Weight
$21
May-10-23 Resumed
Piper Sandler
Overweight
$28
Mar-09-23 Initiated
Wells Fargo
Overweight
$23
Jan-26-23 Initiated
Credit Suisse
Outperform
$29
Oct-18-22 Initiated
JMP Securities
Mkt Outperform
$26
Jun-24-22 Initiated
BMO Capital Markets
Outperform
$28
Nov-19-21 Initiated
Piper Sandler
Overweight
$34
Nov-03-21 Resumed
Jefferies
Buy
$28
Oct-07-21 Initiated
Jefferies
Buy
$28
Aug-06-21 Reiterated
H.C. Wainwright
Buy
$35 → $64
Jun-15-21 Initiated
H.C. Wainwright
Buy
$47
May-18-21 Resumed
Goldman
Sell
$23
Mar-31-21 Initiated
Credit Suisse
Outperform
$30
Mar-12-21 Initiated
Wolfe Research
Outperform
$35
Show Previous Ratings
Apr-16-24 04:05PM
Mar-28-24 08:13AM
Mar-23-24 05:06AM
Mar-17-24 08:50AM
Mar-08-24 09:38AM
08:15AM
Loading…
08:15AM
Mar-07-24 11:31AM
10:08AM
Mar-06-24 04:45PM
Mar-04-24 07:06PM
Mar-02-24 05:06AM
Feb-27-24 04:05PM
08:00AM
Feb-26-24 07:42AM
Feb-23-24 01:11PM
08:00AM
Loading…
Feb-19-24 08:00AM
Feb-14-24 08:30AM
01:47AM
Feb-13-24 08:00AM
Feb-12-24 09:35AM
Feb-10-24 05:06AM
Feb-09-24 09:35AM
Feb-08-24 06:50PM
09:35AM
Feb-07-24 07:01PM
(Morningstar Research) -7.56%
01:13PM
10:47AM
09:45AM
(Thomson Reuters StreetEvents)
Feb-06-24 08:45PM
06:30PM
05:25PM
Loading…
05:25PM
05:01PM
04:33PM
(Associated Press Finance)
04:05PM
Feb-01-24 04:05PM
Jan-30-24 10:00AM
Jan-29-24 09:40AM
Jan-25-24 08:00AM
Jan-23-24 04:05PM
Jan-22-24 05:00PM
Jan-21-24 01:16PM
Jan-19-24 11:21AM
Jan-18-24 04:05PM
04:00PM
Jan-17-24 11:29AM
Jan-11-24 09:40AM
Jan-08-24 04:40PM
(Investor's Business Daily)
12:43PM
06:12AM
Jan-07-24 04:00PM
Jan-02-24 04:05PM
Dec-19-23 10:16AM
Dec-12-23 08:54AM
Dec-07-23 04:05PM
Dec-05-23 01:51PM
Dec-04-23 07:26PM
08:02AM
08:00AM
Dec-01-23 11:32AM
Nov-29-23 10:45AM
Nov-21-23 04:05PM
Nov-17-23 01:33PM
Nov-10-23 09:00AM
Nov-09-23 04:43PM
Nov-08-23 05:24PM
05:19AM
Nov-06-23 09:47AM
Nov-03-23 12:11PM
Nov-02-23 11:23AM
12:30AM
Nov-01-23 07:00PM
06:05PM
04:05PM
Oct-30-23 10:00AM
Oct-28-23 05:06AM
Oct-27-23 04:58AM
Oct-26-23 10:02AM
Oct-25-23 10:01AM
08:30AM
Oct-22-23 02:30AM
Oct-19-23 06:51PM
08:15AM
Oct-18-23 04:05PM
08:30AM
Oct-12-23 11:40AM
Oct-09-23 02:03AM
Oct-02-23 09:49AM
Sep-20-23 02:15PM
Sep-18-23 09:16AM
Sep-16-23 05:06AM
Sep-15-23 10:23AM
Sep-13-23 11:23AM
08:29AM
Sep-12-23 08:00AM
Sep-11-23 12:31PM
Sep-08-23 11:30AM
Sep-07-23 08:43AM
Sep-06-23 09:33AM
Sep-05-23 11:40AM
09:40AM
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Garber Alan M Director Mar 21 '24 Option Exercise 19.57 23,491 459,719 54,908 Mar 25 07:31 PM Garber Alan M Director Mar 21 '24 Sale 24.01 19,205 461,112 35,703 Mar 25 07:31 PM Haley Patrick J. EVP, Commercial Feb 23 '24 Sale 21.45 47,020 1,008,579 384,866 Feb 27 06:58 PM JOHNSON DAVID EDWARD Director Feb 21 '24 Buy 20.70 190,000 3,932,734 1,100,730 Feb 22 05:08 PM Haley Patrick J. EVP, Commercial Dec 14 '23 Option Exercise 16.29 50,000 814,500 357,687 Dec 14 07:56 PM Haley Patrick J. EVP, Commercial Dec 14 '23 Sale 23.35 50,000 1,167,500 307,687 Dec 14 07:56 PM Hessekiel Jeffrey EVP, General Counsel & Sec Dec 13 '23 Sale 23.01 25,000 575,250 533,345 Dec 14 07:55 PM Haley Patrick J. EVP, Commercial Dec 12 '23 Sale 22.50 14,149 318,352 307,687 Dec 14 07:56 PM Hessekiel Jeffrey EVP, General Counsel & Sec Dec 04 '23 Sale 22.06 25,000 551,500 558,345 Dec 04 06:22 PM Hessekiel Jeffrey EVP, General Counsel & Sec Nov 30 '23 Sale 22.01 25,000 550,250 583,345 Dec 04 06:22 PM JOHNSON DAVID EDWARD Director Nov 27 '23 Buy 21.61 120,409 2,602,038 910,730 Nov 29 04:30 PM JOHNSON DAVID EDWARD Director Nov 27 '23 Sale 21.61 120,409 2,602,038 790,321 Nov 29 04:30 PM Aftab Dana CSO/EVP Disc & Trans Research Aug 30 '23 Sale 22.47 4,600 103,362 399,943 Sep 01 08:15 PM MORRISSEY MICHAEL President and CEO Aug 28 '23 Option Exercise 15.31 360,000 5,511,600 945,496 Aug 30 09:48 PM Senner Christopher J. EVP and CFO Aug 04 '23 Option Exercise 14.74 60,000 884,400 631,631 Aug 07 09:20 PM Senner Christopher J. EVP and CFO Aug 04 '23 Sale 20.68 60,000 1,240,800 571,631 Aug 07 09:20 PM Senner Christopher J. EVP and CFO Aug 03 '23 Option Exercise 14.74 60,000 884,400 631,631 Aug 07 09:20 PM Senner Christopher J. EVP and CFO Aug 03 '23 Sale 20.51 60,000 1,230,600 571,631 Aug 07 09:20 PM Haley Patrick J. EVP, Commercial Aug 03 '23 Sale 20.67 30,553 631,531 285,467 Aug 07 08:24 PM Hessekiel Jeffrey EVP, General Counsel & Sec Aug 01 '23 Option Exercise 14.74 55,710 821,165 627,686 Aug 03 08:02 PM Hessekiel Jeffrey EVP, General Counsel & Sec Aug 01 '23 Sale 19.63 55,710 1,093,587 571,976 Aug 03 08:02 PM
Index -
P/E 5.52
EPS (ttm) 1.43
Insider Own 0.04%
Shs Outstand 145.37M
Perf Week 3.54%
Market Cap 1.15B
Forward P/E 3.95
EPS next Y 2.00
Insider Trans 0.00%
Shs Float 145.31M
Perf Month -7.76%
Income 342.60M
PEG 1.35
EPS next Q 0.36
Inst Own 52.07%
Short Float 7.43%
Perf Quarter 7.12%
Sales 1.76B
P/S 0.65
EPS this Y -1.59%
Inst Trans -5.59%
Short Ratio 4.16
Perf Half Y -27.76%
Book/sh 13.81
P/B 0.57
EPS next Y 8.09%
ROA 4.76%
Short Interest 10.80M
Perf Year -45.80%
Cash/sh 22.19
P/C 0.36
EPS next 5Y 4.08%
ROE 10.18%
52W Range 7.12 - 15.46
Perf YTD -20.57%
Dividend Est. 0.40 (5.05% )
P/FCF -
EPS past 5Y -10.96%
ROI 6.52%
52W High -48.88%
Beta 0.42
Dividend TTM -
Quick Ratio 2.38
Sales past 5Y 1.84%
Gross Margin 78.73%
52W Low 10.94%
ATR (14) 0.38
Dividend Ex-Date Apr 11, 2024
Current Ratio 2.38
EPS Y/Y TTM 296.59%
Oper. Margin 26.87%
RSI (14) 45.79
Volatility 3.86% 4.22%
Employees -
Debt/Eq 0.78
Sales Y/Y TTM -4.17%
Profit Margin 19.47%
Recom 2.04
Target Price 12.17
Option/Short Yes / Yes
LT Debt/Eq 0.55
EPS Q/Q -42.77%
Payout 0.00%
Rel Volume 0.83
Prev Close 8.06
Sales Surprise 1.45%
EPS Surprise -38.43%
Sales Q/Q 3.50%
Earnings Mar 14 BMO
Avg Volume 2.60M
Price 7.90
SMA20 -2.84%
SMA50 -4.35%
SMA200 -21.58%
Trades
Volume 2,152,665
Change -1.99%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-28-24 Downgrade
Goldman
Buy → Neutral
Mar-19-24 Upgrade
UBS
Neutral → Buy
$11.50
Jan-11-24 Downgrade
BofA Securities
Buy → Underperform
$19.50 → $10
Aug-25-23 Downgrade
The Benchmark Company
Buy → Hold
Jun-13-23 Downgrade
UBS
Buy → Neutral
$33 → $15.50
Jan-30-23 Initiated
JP Morgan
Neutral
Jan-09-23 Upgrade
Goldman
Neutral → Buy
$25
Apr-11-22 Resumed
Goldman
Neutral
$37.50
Mar-11-22 Downgrade
UBS
Buy → Neutral
$64 → $27.80
Aug-19-21 Upgrade
Credit Suisse
Neutral → Outperform
$48 → $56
Sep-29-20 Upgrade
CLSA
Outperform → Buy
Apr-22-20 Downgrade
Barclays
Overweight → Equal Weight
$47 → $40
Nov-15-19 Downgrade
CLSA
Buy → Outperform
Nov-14-19 Downgrade
Credit Suisse
Outperform → Neutral
Oct-18-19 Upgrade
Jefferies
Hold → Buy
Oct-04-19 Upgrade
Credit Suisse
Neutral → Outperform
Aug-19-19 Upgrade
CLSA
Outperform → Buy
Aug-05-19 Initiated
Jefferies
Hold
May-28-19 Downgrade
JP Morgan
Overweight → Neutral
May-24-19 Reiterated
The Benchmark Company
Buy
$81 → $51
Show Previous Ratings
Apr-19-24 04:04AM
Apr-14-24 12:06AM
Apr-12-24 11:09AM
Apr-08-24 05:45AM
Apr-01-24 03:32PM
10:24PM
Loading…
Mar-31-24 10:24PM
Mar-27-24 06:52AM
(Thomson Reuters StreetEvents)
Mar-22-24 07:07AM
Mar-19-24 11:55PM
11:42PM
Mar-14-24 09:30AM
05:00AM
Mar-12-24 11:29PM
07:43AM
Mar-11-24 09:55PM
04:00AM
Loading…
Feb-27-24 04:00AM
Feb-23-24 05:27PM
04:30AM
(South China Morning Post)
Feb-20-24 02:38AM
Feb-11-24 06:23AM
Feb-04-24 04:03AM
Jan-04-24 04:30AM
(South China Morning Post)
Dec-21-23 04:30AM
(South China Morning Post)
01:32AM
Dec-20-23 09:14PM
Dec-18-23 08:36AM
Dec-14-23 11:18PM
Nov-30-23 08:56AM
08:55AM
Nov-29-23 04:21PM
04:19PM
Loading…
04:19PM
Nov-27-23 11:16AM
02:05AM
Nov-13-23 07:11PM
Nov-10-23 02:48PM
Nov-09-23 09:30AM
04:00AM
Nov-02-23 02:46AM
Nov-01-23 05:30AM
(South China Morning Post)
Oct-31-23 06:48PM
08:20AM
07:11AM
Oct-27-23 12:23AM
(Associated Press Finance)
Oct-26-23 09:40AM
Oct-25-23 11:40AM
09:55AM
05:00AM
Oct-24-23 12:44AM
Oct-20-23 06:18AM
Oct-05-23 12:01PM
Sep-30-23 10:50AM
Sep-22-23 12:35PM
Sep-07-23 05:30AM
(South China Morning Post) -5.72%
Aug-25-23 11:48AM
09:39AM
Aug-24-23 05:15AM
Aug-18-23 04:36AM
Aug-09-23 05:00AM
Aug-08-23 04:20PM
Aug-01-23 11:54PM
Jun-26-23 10:09PM
Jun-23-23 02:54PM
May-25-23 05:00AM
May-24-23 04:30AM
May-10-23 09:40AM
May-05-23 05:00AM
May-01-23 11:40AM
Apr-27-23 05:30AM
Apr-21-23 06:43AM
Apr-20-23 01:59AM
Apr-14-23 11:40AM
Apr-03-23 05:30AM
Mar-31-23 05:30AM
(South China Morning Post)
Mar-29-23 11:40AM
Mar-22-23 10:04AM
Mar-21-23 11:45AM
(The Wall Street Journal)
11:45AM
(The Wall Street Journal)
10:00AM
(The Wall Street Journal)
Mar-06-23 10:13PM
04:30AM
(South China Morning Post)
Mar-02-23 04:30AM
(South China Morning Post)
Mar-01-23 07:29AM
04:45AM
Feb-28-23 08:36AM
08:00AM
Feb-21-23 04:00PM
Feb-15-23 04:00AM
Jan-27-23 09:36AM
08:57AM
06:00AM
Jan-23-23 11:40AM
Dec-31-22 02:44AM
Dec-27-22 01:21PM
Dec-26-22 08:46PM
Dec-21-22 11:35AM
Dec-14-22 01:19AM
Dec-13-22 01:10AM
01:05AM
Dec-07-22 04:56AM
Dec-02-22 09:30AM
Weibo Corp. engages in the creation, distribution, and discovery of Chinese-language content. It operates through the Advertising and Marketing Services, and Other Services segments. The company was founded in August 2009 and is headquartered in Beijing, China.
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite